IPP Bureau
Apollo Hospitals integrates cardiovascular risk tool with ConnectedLife digital wellness solutions
By IPP Bureau - July 06, 2022
The AICVD tool can predict the risk of cardiovascular disease.
Vaccizone selects Exothera for GMP manufacturing of its SARS?CoV?2 vaccine
By IPP Bureau - July 06, 2022
Vaccizone’s ASC Technology is an enhanced antigen/bioactive delivery method based on Antigen Presenting Cells
.jpg "ART Fertility Clinics appoints Dr. Somesh Mittal as CEO, India")
ART Fertility Clinics appoints Dr. Somesh Mittal as CEO, India
By IPP Bureau - July 05, 2022
Mittal has previously managed Multiple backed Vikram Hospital as CEO and was associated with Fortis Escorts Heart Institute as zonal director.
50% of heart attacks now happens in Indians below 50 years: says Expert
By IPP Bureau - July 05, 2022
Younger Indians have a 10 times higher rate of heart attack
Apollo Hospitals Navi Mumbai performs first minimally invasive mitral heart valve replacement
By IPP Bureau - July 05, 2022
Transcatheter Mitral valve procedure allows intervention on patients who are unsuitable or high risk for open heart surgery
Need for national-level awareness about organ transplant surgeries & organ donation in India
By IPP Bureau - July 05, 2022
People in India are still wary of organ transplants. So, there is an urgent need of increased public awareness.
Novavax aims COVID vaccine on Omicron in Q4
By IPP Bureau - July 05, 2022
The vaccine is under FDA review
Sanofi Global Health launches nonprofit Impact brand for 30 medicines in low-income countries
By IPP Bureau - July 05, 2022
Medicines, including insulin, to be available in 40 lower-income countries
Sanofi flu vaccines licensed and approved for 2022-2023 influenza season
By IPP Bureau - July 05, 2022
Sanofi will begin to ship their vaccines helping to ensure more people will be immunized
OliX Pharmaceuticals submits application to U.S. FDA to evaluate safety and tolerability of OLX10212
By IPP Bureau - July 04, 2022
The objective of this Phase 1 study is to determine the safety and tolerability of OLX10212 in patients with advanced AMD at multiple sites in the US.
Clinical study of PD-L1 antibody ASC22 for cure of HIV completes first patient dosing
By IPP Bureau - July 04, 2022
Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection
USFDA conducts inspection at Glenmark's Aurangabad manufacturing facility
By IPP Bureau - July 04, 2022
The company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe.
.jpg "Microsize launched as Independent pharma services company"){kind=logo}
Microsize launched as Independent pharma services company
By IPP Bureau - July 04, 2022
Meets the growing need for US-based API solubility and bioavailability enhancement services
Pfizer submits new drug application to the U.S. FDA for Paxlovid
By IPP Bureau - July 03, 2022
Submission seeks approval for the treatment of COVID-19 in both vaccinated and unvaccinated individuals at high risk
Pfizer to achieve net-zero standard by 2040
By IPP Bureau - July 03, 2022
Pfizer aims to achieve net-zero targets ten years earlier than the expectations of the Net-Zero Standard
